Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine effects on serum histamine and serotonin in hemodialysis patients with chronic kidney disease
IRCT20150629022965N18Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirtazapine in chronic kidney disease (CKD), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Serum histamine level and Serum serotonin level. Started May 2018; status: completed.
02
Drugs
mirtazapine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20150629022965N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150629022965N18.